Calithera Biosciences Inc
NASDAQ:CALA
Intrinsic Value
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor a... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CALA.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Calithera Biosciences Inc's business.
What risks and challenges
does Calithera Biosciences Inc face in the near future?
Summarize the latest earnings report
of Calithera Biosciences Inc.
Provide P/E
for Calithera Biosciences Inc and its competitors.
Balance Sheet Decomposition
Calithera Biosciences Inc
Current Assets | 26.6m |
Cash & Short-Term Investments | 25.5m |
Other Current Assets | 1.1m |
Non-Current Assets | 2.1m |
PP&E | 1.8m |
Other Non-Current Assets | 300k |
Current Liabilities | 7.4m |
Accounts Payable | 700k |
Accrued Liabilities | 6.7m |
Non-Current Liabilities | 900k |
Other Non-Current Liabilities | 900k |
Earnings Waterfall
Calithera Biosciences Inc
Revenue
|
0
USD
|
Operating Expenses
|
-42.1m
USD
|
Operating Income
|
-42.1m
USD
|
Other Expenses
|
20.8m
USD
|
Net Income
|
-21.3m
USD
|
Free Cash Flow Analysis
Calithera Biosciences Inc
What is Free Cash Flow?
CALA Profitability Score
Profitability Due Diligence
Calithera Biosciences Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Calithera Biosciences Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
CALA Solvency Score
Solvency Due Diligence
Calithera Biosciences Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
Calithera Biosciences Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CALA Price Targets Summary
Calithera Biosciences Inc
Ownership
CALA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CALA Price
Calithera Biosciences Inc
Average Annual Return | -55.04% |
Standard Deviation of Annual Returns | 27.01% |
Max Drawdown | -100% |
Market Capitalization | 98k USD |
Shares Outstanding | 4 872 500 |
Percentage of Shares Shorted | 8.92% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. The company is headquartered in South San Francisco, California and currently employs 63 full-time employees. The company went IPO on 2014-10-02. The Company’s is engaged in discovering and development of targeted therapies, which disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. The firm is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. The Company’s principal operations are based in South San Francisco, California. The company has a range of pipeline of small molecule drug candidates, which target enzymes controlling metabolically critical pathways in tumor cells and immune cells. The company has multiple internally discovered clinical stage compounds that are all enzyme inhibitors. The firm is engaged in developing telaglenastat in combination with standard therapies in a select set of solid tumors. Its lead development pathway for telaglenastat is for the treatment of KEAP1 or NRF2 mutated non-small cell lung cancer (NSCLC).